Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Schleis, T
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schleis, T

Letters

Realities of the fluoxetine-to-sertraline switch

T Schleis

You have reached the most complete version of this article accessible.



This article has been cited by other articles:


Home page
 DiabetesHome page
V. J. Briscoe, A. C. Ertl, D. B. Tate, and S. N. Davis
Effects of the Selective Serotonin Reuptake Inhibitor Fluoxetine on Counterregulatory Responses to Hypoglycemia in Individuals With Type 1 Diabetes
Diabetes, December 1, 2008; 57(12): 3315 - 3322.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Schleis, T
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schleis, T